[HTML][HTML] Update on global epidemiology of viral hepatitis and preventive strategies
M Jefferies, B Rauff, H Rashid, T Lam… - World journal of clinical …, 2018 - ncbi.nlm.nih.gov
Viral hepatitis is one of the major public health concerns around the world but until recently it
has drawn little attention or funding from global health policymakers. Every year 1.4 million …
has drawn little attention or funding from global health policymakers. Every year 1.4 million …
Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions
Egypt is the most affected nation by hepatitis C virus (HCV) and needs a comprehensive
characterization of HCV epidemiology to inform the scale-up of treatment and prevention …
characterization of HCV epidemiology to inform the scale-up of treatment and prevention …
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Background Despite revised guidelines that no longer exclude people who inject drugs
(PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to …
(PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to …
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
AD Marshall, EB Cunningham, S Nielsen… - The lancet …, 2018 - thelancet.com
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates
of 95% or more, represent a major clinical advance. However, the high list price of DAAs has …
of 95% or more, represent a major clinical advance. However, the high list price of DAAs has …
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
Background & Aims Direct-acting antiviral therapies (DAA) are an important tool for hepatitis
C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may …
C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may …
Evaluation of the Xpert HCV viral load finger-stick point-of-care assay
FMJ Lamoury, S Bajis, B Hajarizadeh… - The Journal of …, 2018 - academic.oup.com
Point-of-care hepatitis C virus (HCV) RNA testing is advantageous, enabling diagnosis of
active infection in a single visit. This study evaluated the sensitivity and specificity of the …
active infection in a single visit. This study evaluated the sensitivity and specificity of the …
The removal of DAA restrictions in Europe–one step closer to eliminating HCV as a major public health threat
Of∼ 10.2 million people with chronic HCV infection in Europe, 6.7 million live in Eastern
Europe, 2.3 million in Western Europe and 1.2 million in Central Europe. HCV transmission …
Europe, 2.3 million in Western Europe and 1.2 million in Central Europe. HCV transmission …
Management of acute HCV infection in the era of direct-acting antiviral therapy
The management of acute HCV infection has not been standardized following the
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …
Hepatitis b and c
KR Mysore, DH Leung - Clinics in Liver Disease, 2018 - liver.theclinics.com
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent a major global
public health and economic burden, with an estimated 257 million and 71 million people …
public health and economic burden, with an estimated 257 million and 71 million people …
Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?
S Christensen, P Buggisch, S Mauss, KHW Böker… - …, 2018 - Wiley Online Library
Background and aims There is limited real‐world information on the effectiveness of antiviral
treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals (DAA) in …
treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals (DAA) in …